Fei Yang

10PUBLICATIONS
63CO-AUTHORS
Cancer diagnosisTumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 24, 2025
Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.

Tanvi H Visal, Recep Bayraktar, Petra den Hollander

|Dec 16, 2022
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.

Xiaoping Wang, Takashi Semba, Ganiraju C Manyam

|Jun 23, 2022
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.

Tapsi Kumar, Evie Hobbs, Fei Yang

|May 10, 2022
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.

Xuan Liu, Zhongqi Ge, Fei Yang

|Nov 28, 2021
Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.

Xiangjie Sun, Jie Zhai, Baohua Sun

|Jul 13, 2021
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.

Clinton Yam, Er-Yen Yen, Jeffrey T Chang

Pageof 2

Frequent Collaborators

4 joint publications

Edwin Roger Parra Cuentas

2 joint publications

Maria Gabriela Raso

2 joint publications

Jennifer L Guerriero

2 joint publications

Naoto T Ueno